|
Last
Update:
August 08, 2011
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
6th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
Lower levels of circulating
inflammatory biomarkers are associated with persistently lower HDL
concentrations after initiation of antiretroviral therapy
C. Fichtenbaum, K. Nowak, L. Rusie, et al
Poster
Abstract
POSTER
Lower body fat mass and lower bone formation predict greater bone
loss with tenofovir in HIV-infected adults
H. Haskelberg, J. Hoy, J. Amin, et al
Poster
Abstract
Adherence/drug detection rates and study participant experiences
of counseling support among MSM in the iPrEx pre-exposure
prophylaxis (PrEP) trial in San Francisco, United States
H. Gilmore, A. Liu, K.R. Amico, et al
Abstract
Adherence
challenges to daily and intermittent pre-exposure prophylaxis
(PrEP) in men who have sex with men and female sex workers in
Kenya
E.M. Van der Elst, G. Mutua, P. Mugo, et al
Abstract
Risk
compensation and pre-exposure prophylaxis (PrEP): a post-iPrEx
survey of US men who have sex with men (MSM)
R. Irvin, A. Liu,, L. Kroboth, et al
Abstract
Expanded
case-control analysis of drug detection in the global iPrEx trial
P.L. Anderson, J.R. Lama, S. Buchbinder. et al
Abstract
Changes
in bone mineral density after 96 weeks of treatment with tenofovir
DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir
in HIV-1 infected treatment naïve subjects: the CASTLE body
composition sub-study
G. Moyle, D. Ward, A. Farajallah
Abstract
Hair as a
biological marker of daily oral pre-exposure prophylaxis (PrEP)
adherence and tenofovir/emtricitabine (TFV/FTC) exposure in the
Global iPrEx Study
A. Liu, Y. Huang, P. Defechereux. et al
Abstract
Non-treatment limiting symptoms associated with biomarkers of
inflammation are more frequently reported in persons with advanced
AIDS shortly after initiating HAART
K. Nowak, C. Fichtenbaum, L. Rusie, et al
Abstract
-
A WEEK-IN-REVIEW FEATURED REPORT
Central Fat
Accumulation in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC
with ATV/r or EFV: ACTG A5224s, a Substudy of ACTG A5202
G McComsey, D Kitch, P Sax.
et al
Abstract
-
Pre-exposure
Chemprophylaxis for Prevention of HIV among Trans-women and MSM: iPREx Study
R Grant,
J Lama, D Glidde, and iPrEx Study Team
Abstract
-
Complete Protection against Rectal Transmission of an
Emtricitabine-resistant SHIV162p3-M184V Mutant
by Intermittent
Prophylaxis with Truvada
M-E Cong, A Youngpairoj, Q Zheng, et
al
Abstract
-
Effects of FTC/TDF on Bone Mineral Density in Seronegative Men
from 4 Continents:
DEXA Results of the Global iPrEx Study
K Mulligan, D
Glidden, P Gonzales, et al
Abstract
-
Interpreting
Detection Rates of Intracellular FTC-TP and TFV-DP: The iPrEx Trial
P Anderson, J Lama, S
Buchbinde, et al
Abstract
XVIII International AIDS Conference
|
- A WEEK-IN-REVIEW
FEATURED REPORT
POSTER
Switching from Kivexa [ABC/3TC ]+Kaletra
[LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] reduces
high cholesterol: results of a 12 week randomized, controlled study (ROCKET II)
G. Behrens, R. Maserati, A. Rieger, et al
PDF Poster
Abstract
POSTER
Safety and adherence to intermittent emtricitabine/tenofovir for HIV
pre-exposure prophylaxis (PrEP) |
in Kenya and Uganda
G. Mutua, E.J. Sanders, A. Kamali, et al
PDF Poster
Abstract
POSTER
The partners PrEP study: enrollment of HIV-1 serodiscordant
couples into a phase III, randomized
trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
J. Baeten, N. Mugo, P. Ndase, et al
PDF Poster
Abstract
Exposure of extracellular and intracellular tenofovir and emtricitabine in
mucosal tissues after a single
of fixed-dose TDF/FTC: implications for pre-exposure HIV prophylaxis (PrEP)
K. Patterson, H. Prince, E. Kraft, et al
Incidence
of emtricitabine, tenofovir, raltegravir, and lopinavir resistance following
twice-daily (BID)
lopinavir/ritonavir (LPV/r) in combination with once-daily (QD)
emtricitabine/tenofovir (FTC/TDF) or
twice daily raltegravir (RAL) in antiretroviral-naïve, HIV-1 infected subjects:
48-week results of a 96-week
randomized trial (study M10-336)
A. Lawal, L. Maroldo, R. Rivero, et al
Virological response to atazanavir, ritonavir and tenofovir/emtricitabine:
relation to individual
pharmacokinetic parameters and adherence measured by medication events
monitoring system (MEMS)
in naïve HIV-infected patients (ANRS134 trial)
C. Goujard, A. Barrail-Tran, X. Duval, et al
Bioequivalence of the co-formulation of
emtricitabine/rilpivirine/tenofovir DF
A. Mathias, M. Menning, X. Wei, et al
- POSTER
Risk of
Virological Failure of Antiretroviral Regimens including Nevirapine, Tenofovir,
and
Emtricitabine (or Lamivudine) in Previously Treated HIV-1-infected Patients
J Llibre, J Santos, R
Martin-Iguacel, et al
PDF
Poster
Abstract
5th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
- POSTER
Kivexa versus truvada: similar virological outcomes in ART-naïve patients
starting a
lopinavir/ritonavir-based regimen - 48-week-data from the STAR and Stella
cohorts
C. Koegl, A. Baumgarten, B. Bieniek, et al
PDF Poster
Abstract
-
Combination therapy
with tenofovir DF (TDF)/ emtricitabine (FTC) and efavirenz leads to
sustained and
favourable responses in a large outpatient cohort (German TRUVADA cohort)
A. Zoufaly, S. Hertling, G. Faetkenheuer, et al
-
The TOKEN study:
safety & efficacy of Truvada Or Kivexa in combination with
Efavirenz in treatment Naïve predominantly black African HIV
patients, a prospective cohort study
S. Das, J. Arumainayagam, I. Ahmed-Jushuf, et al
-
Tolerability of
post-exposure prophylaxis (PEP) of HIV infection with the combination of
tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation (Truvada +
Kaletra)
W. Tosini, P. Muller, T. Prazuck, et al
-
Tenofovir
DF/emtricitabine/raltegravir (TDF/FTC/RAL) appears safe and well-tolerated for
non-occupational
post-exposure prophylaxis (NPEP)
K. Mayer, M. Mimiaga, M. Gelman, et al
|
Ninth International Congress on Drug Therapy in HIV Infection
|
-
Efficacy and safety of TDF/FTC-containing first-line HAART in clinical practice
– 2-year data
from the German Outpatient Cohort
van Lunzen J, Fätkenheuer G, Lutz T, et al
Abstract
-
Similar virological
response rates for ART-naïve subjects starting KVX + LPV/r or TVD+ LPV/r.
Data from the prospective observational STAR cohort
Wolf E, Trein A, Schmidt W, Baumgarten A, et
a
Abstract
-
Cost-effectiveness of
tenofovir/emtricitabine compared with other NRTI pairs in treatment-naïve adults
with HIV infection in the USA
Brogan AJ, Everhard F, Talbird SE, et al
Abstract
-
The TOKEN study:
safety and efficacy of Truvada or Kivexa in combination with efavirenz in
treatment-naïve
predominantly black African HIV patients
Das S, Arumainayagam J, Kumari B, et a
Abstract
-
Efficacy and safety of
tenofovir/emtricitabine compared to abacavir/lamivudine in HIV-1 infected
patients in
clinical setting. The TEAL study
Eccleston KJ, Bambumba A, Babu CS, et al
Abstract
-
Immune and virologic
responses to Truvada or Combivir as a first-line therapy of HIV-infected,
treatment-naïve patients
Maserati R, Clerici M, Lauriola M, et al
Abstract
-
Efficacy and safety of
Truvadain HIV-1 pregnant women: report of 23 cases
Ciraru-Vigneron N, Mazeron
MC, Lefevre V, et al
Abstract
XVII International AIDS Conference
|
-
One year comparative hematological and renal safety of tenofovir +
emtricitabine versus zidovudine +
amivudine in HIV-1 infected patients on first line nevirapine or efavirenz
based therapy in Thailand
G. Jourdain B. Leurent, V. Klinbuayaem, et al
Abstract
-
Transform: alterations in fat distribution over 48 weeks following
substitution of tenofovir DF/emtricitabine
for didanosine/lamivudine in HIV-infected patients on a common efavirenz
background
D. Park, C.
Jennings, C. Taylor, et al
Abstract
-
Simplification with easier emtricitabine and tenofovir (SWEET): results of a 48
week analysis of patients’
perceptions of treatment and adherence
V.L. Cooper, R. Horne, G. Moyle, et al
Abstract
-
The LOLITA trial: a pilot study assessing the safety and adherence of a once
daily regimen including tenofovir
and emtracitabine (TDF+FTC), boosted atazanavir (ATV) as a post exposure
prophylaxis (PEP)
J.-M. Livrozet, N. Berra, F. Brunel, et al
Abstract
-
Renal function in treatment-naive subjects exposed to tenofovir (TFV)/
emtricitabine in combination with
atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r): 48-week results
from the CASTLE study (BMS AI424138)
D.
McGrath, L. Zhu, A. Thiry, et al
Abstract
4th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
Efficacy and safety of NRTI´s switch to tenofovir plus emtricitabine
(Truvada(R)) vs. abacavir plus
lamivudine (Kivexa(R)) in patients with virologic suppression receiving a
lamivudine containing HAART:
the BICOMBO study
Martinez E., Arranz JA, Podzamczer D.
Abstract
Efficacy of tenofovir/emtricitabine containing ART regimen in cerebrospinal
fluid (CSF)
Nolting T., Arendt GR.
Abstract
Better adherence to both tenofovir/emtricitabine and to efavirenz in
individuals taking tenofovir/
emtricitabine fixed dose nucleoside combination tablet
Keiser P., Armas L., Sanchez J, et al
Abstract
8th Int Congress on Drug Therapy in HIV
Infection
|
E DeJesus, S Sharma, R Corales, et al
Abstract
Virologic suppression is maintained in antiretroviral experienced adults
who change from
tenofovir and lamivudine to Truvada, a once daily fixed-dose combination
tablet of tenofovir
and emtricitabine
AE Colson, CJ Cohen, C Martorell, et al
Abstract
Cost-effectiveness analysis of tenofovir/emtricitabine and
abacavir/lamivudine in the treatment of
antiretroviral nave HIV-1
infected patients
J Borrill, R A O'Donnell, C Avila, et al
Abstract
XVI
International AIDS Conference
|
-
Experience with tenofovir DF (TDF) + emtricitabine (FTC) in
antiretroviral-naïve patients at Uganda
cares, a rural African HIV
treatment program
Okongo B., Iutung P., Katete H., et al
Abstract
-
Benefits of switching different nuke - backbones to a
tenofovir/emtricitabine (Truvada®) containing
regimen
Rump J.-A., Usadel S.
Abstract
-
Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and
efavirenz (EFV) compared to fixed
dose zidovudine/lamivudine (CBV)
and EFV through 96 weeks in antiretroviral treatment-naïve patients
Gallant J., Pozniak A., DeJesus E., et al
Abstract
-
Effects of switching from fixed dose zidovudine/lamivudine (CBV) to
fixed dose tenofovir DF/
emtricitabine (TVD): maintenance of
virologic suppression and other benefits
DeJesus E., Ruane P., McDonald C., et al
Abstract
-
Switching stable Combivir patients to tenofovir/ emtricitabine: a
48-week pilot study
Scott J., Guyer B., Bethel J, et al
-
Creatine elevations in patients on fixed dose
tenofovir/emtricitabine (Truvada) or tenofovir
Piontkowsky D., Doran B., Heintz J.
Abstract
-
Lack of clinically relevant drug-drug interaction between
ritonavir-boosted GS-9137 (GS-9137/r)
and emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF)
S. Ramanathan, J. Skillington, A. Plummer, et al
Abstract
|
|
|
Tenofovir Disoproxil Fumarate/Emtricitabine
(Truvada)
Conference Citations |
|
Truvada Main Page
Main
New/Newsworthy
